Navigation Links
Animal Eggs Not Suitable Substitutes to Produce Stem Cells
Date:2/2/2009

NEW ROCHELLE, N.Y., Feb. 2 /PRNewswire/ -- Since the cloning of Dolly the Sheep over a decade ago, somatic cell nuclear transfer (SCNT) has been considered a promising way to generate human, patient-specific stem cells for therapeutic applications. The shortage of human donor eggs has led to efforts to substitute animal oocytes. However, a new study published online ahead of print in the Volume 11, Number 2, 2009 issue of Cloning and Stem Cells, a peer-reviewed journal published by Mary Ann Liebert, Inc., demonstrates that animal oocytes lack the capacity to fully reprogram adult human cells. The paper is available free online at www.liebertpub.com/clo

Robert Lanza, M.D. and colleagues from Advanced Cell Technology (Worcester, MA), Wake Forest University School of Medicine (Winston Salem, NC), Reproductive Medicine Associates of New Jersey (Morristown), Fertility Specialists of Houston (Texas), Stem Cell Source (Houston), and the College of Veterinary Medicine and Biomedical Sciences at Texas A&M University (College Station), compared the reprogramming of human cells using oocytes obtained from cows, rabbits, and humans. They report their findings in a paper entitled, "Reprogramming of Human Somatic Cells Using Human and Animal Oocytes."

The ability to reprogram human cells using oocytes would enable the production of patient-specific stem cells that could then be differentiated to become any type of somatic cell and used for cell or tissue repair or placement therapy. This extensive reprogramming requires that the oocyte turn on, or up-regulate a large number of genes in the donor nucleus.

Although previous reports have documented the formation of cloned embryos using both human and animal eggs, to date, there have been no data indicating to what extent the donor human DNA was reprogrammed. Lanza et al. show for the first time that human oocytes have the capacity to change these patterns of gene expression, and that interspecies (human-to-animal) cloning does not produce the same results. Although the human-bovine and human-rabbit clones looked similar to the human-human embryos, the human-animal hybrids did not exhibit the changes in gene expression seen in the human-human clones and normal embryos. Specifically, they did not achieve up-regulation of critical pluripotency-associated genes needed for stem cell production.

"This very important paper suggests that livestock oocytes are extremely unlikely to be suitable as recipients for use in human nuclear transfer. This is very disappointing because it would mean that production of patient-specific stem cells by this means would be impracticable,"

says Ian Wilmut, Ph.D., Editor-in-Chief of Cloning and Stem Cells and director of the Centre for Regenerative Medicine, in Edinburgh.

Cloning and Stem Cells is an authoritative peer-reviewed journal published quarterly in print and online that focuses on understanding developmental plasticity and defining the molecular mechanisms that regulate differentiation or dedifferentiation of nuclei and cells. Tables of contents and a free sample issue may be viewed online at www.liebertpub.com/clo

Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Stem Cells and Development, and Tissue Engineering. Its biotechnology trade magazine, Genetic Engineering and Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT

Contact: Julia Chapman, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2147, jchapman@liebertpub.com


'/>"/>
SOURCE Mary Ann Liebert, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
2. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. Odyssey Thera Granted U.S. Patent for Animal Imaging
5. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
6. Researchers use magnetism to target cells to animal arteries
7. Smithfield Foods, Inc. Statement Regarding Animal Cloning
8. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
9. Animal Protection Groups Condemn FDAs Endorsement of Animal Cloning
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... MA and Azusa, CA (PRWEB) , ... December ... ... provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, today ... Company , will be the first to use Cambrian’s novel water-energy purchase agreement ...
(Date:12/7/2016)... ... December 07, 2016 , ... Proscia ... a new service to enable rapid migration of large pathology data sets to ... of the factors limiting adoption of digital pathology. Proscia’s free massive dataset migrator ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... http://www.autoreactors.com and online shopping cart. The new website has been designed ... These essential digital components allow customers to access detailed product information, read educational ...
(Date:12/7/2016)... Francisco, CA (PRWEB) , ... ... ... leader uBiome is opening applications to an early access program for SmartBiome ... of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of hundreds ...
Breaking Biology Technology:
(Date:12/6/2016)... Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today ... principal amount of its 1.414% senior unsecured notes due 2022 ... notes due 2026. The closing of the ... the satisfaction of customary closing conditions.  The notes will pay ... The Company intends to use the net proceeds from the ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):